264 related articles for article (PubMed ID: 24778280)
1. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
Chen H; Fu T; Suh WK; Tsavachidou D; Wen S; Gao J; Ng Tang D; He Q; Sun J; Sharma P
Cancer Immunol Res; 2014 Feb; 2(2):167-76. PubMed ID: 24778280
[TBL] [Abstract][Full Text] [Related]
2. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.
Ng Tang D; Shen Y; Sun J; Wen S; Wolchok JD; Yuan J; Allison JP; Sharma P
Cancer Immunol Res; 2013 Oct; 1(4):229-34. PubMed ID: 24777852
[TBL] [Abstract][Full Text] [Related]
3. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
Fu T; He Q; Sharma P
Cancer Res; 2011 Aug; 71(16):5445-54. PubMed ID: 21708958
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Carthon BC; Wolchok JD; Yuan J; Kamat A; Ng Tang DS; Sun J; Ku G; Troncoso P; Logothetis CJ; Allison JP; Sharma P
Clin Cancer Res; 2010 May; 16(10):2861-71. PubMed ID: 20460488
[TBL] [Abstract][Full Text] [Related]
5. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
Fan X; Quezada SA; Sepulveda MA; Sharma P; Allison JP
J Exp Med; 2014 Apr; 211(4):715-25. PubMed ID: 24687957
[TBL] [Abstract][Full Text] [Related]
6. Inducible Costimulator Expressing T Cells Promote Parasitic Growth During Blood Stage
Jogdand GM; Sengupta S; Bhattacharya G; Singh SK; Barik PK; Devadas S
Front Immunol; 2018; 9():1041. PubMed ID: 29892278
[TBL] [Abstract][Full Text] [Related]
7. ICOS regulates the generation and function of human CD4+ Treg in a CTLA-4 dependent manner.
Zheng J; Chan PL; Liu Y; Qin G; Xiang Z; Lam KT; Lewis DB; Lau YL; Tu W
PLoS One; 2013; 8(12):e82203. PubMed ID: 24312642
[TBL] [Abstract][Full Text] [Related]
8. T helper cell-specific regulation of inducible costimulator expression via distinct mechanisms mediated by T-bet and GATA-3.
Tan AH; Goh SY; Wong SC; Lam KP
J Biol Chem; 2008 Jan; 283(1):128-136. PubMed ID: 17986443
[TBL] [Abstract][Full Text] [Related]
9. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
[TBL] [Abstract][Full Text] [Related]
10. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.
Shi LZ; Goswami S; Fu T; Guan B; Chen J; Xiong L; Zhang J; Ng Tang D; Zhang X; Vence L; Blando J; Allison JP; Collazo R; Gao J; Sharma P
Cancer Immunol Res; 2019 Nov; 7(11):1803-1812. PubMed ID: 31466995
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
13. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
[TBL] [Abstract][Full Text] [Related]
14. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.
Paulos CM; Carpenito C; Plesa G; Suhoski MM; Varela-Rohena A; Golovina TN; Carroll RG; Riley JL; June CH
Sci Transl Med; 2010 Oct; 2(55):55ra78. PubMed ID: 20980695
[TBL] [Abstract][Full Text] [Related]
15. Inducible costimulator (ICOS) and ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production.
Maeda S; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K; Hasegawa M
Am J Pathol; 2011 Nov; 179(5):2360-9. PubMed ID: 21925472
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
17. Repressor of GATA-3 can negatively regulate the expression of T cell cytokines through modulation on inducible costimulator.
Zang YS; Fang Z; Liu YA; Li B; Xiu QY
Chin Med J (Engl); 2012 Jun; 125(12):2188-94. PubMed ID: 22884151
[TBL] [Abstract][Full Text] [Related]
18. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 antibody ipilimumab negatively affects CD4
Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
[TBL] [Abstract][Full Text] [Related]
20. Anti-chlamydial Th17 responses are controlled by the inducible costimulator partially through phosphoinositide 3-kinase signaling.
Gao X; Gigoux M; Yang J; Leconte J; Yang X; Suh WK
PLoS One; 2012; 7(12):e52657. PubMed ID: 23285133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]